--- title: "TriSalus Life Sciences - CW | 8-K: FY2026 Q1 Revenue: USD 8.899 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286148597.md" datetime: "2026-05-12T20:05:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286148597.md) - [en](https://longbridge.com/en/news/286148597.md) - [zh-HK](https://longbridge.com/zh-HK/news/286148597.md) --- # TriSalus Life Sciences - CW | 8-K: FY2026 Q1 Revenue: USD 8.899 M Revenue: As of FY2026 Q1, the actual value is USD 8.899 M. EPS: As of FY2026 Q1, the actual value is USD 0.03. EBIT: As of FY2026 Q1, the actual value is USD -7.139 M. ### Financial and Operational Metrics for Q1 2026 #### Gross Profit and Margin TriSalus Life Sciences reported a gross profit of $7.669 million for the three months ended March 31, 2026, which was a slight decrease from $7.672 million in the same period of 2025. The gross margin improved to 86.2% in Q1 2026, up from 83.7% in Q1 2025, primarily due to a lower average cost per TriNav unit. #### Operating Expenses Research and development expenses increased to $3.216 million in Q1 2026, compared to $3.021 million in Q1 2025. Sales and marketing expenses rose to $7.413 million in Q1 2026 from $6.734 million in Q1 2025, driven by commercial expansion. General and administrative expenses also increased to $5.451 million in Q1 2026 from $5.246 million in Q1 2025. #### Operating Loss Loss from operations for Q1 2026 was - $8.411 million, an increase in loss compared to - $7.329 million for the same period in 2025. This increase was mainly due to higher sales and marketing expenses and increased non-cash stock-based compensation, partially offset by improved gross margins. #### Net Income (Loss) Attributable to Common Stockholders Net income attributable to common stockholders was $1.539 million for Q1 2026, a significant improvement from a net loss of - $11.087 million in Q1 2025. This change was primarily due to $11.3 million in non-cash gains related to changes in the fair value of various derivatives in the current period, compared to - $1.7 million in losses for the same period in 2025. #### Adjusted EBITDA Adjusted EBITDA losses for Q1 2026 were - $5.804 million, compared to losses of - $5.537 million for Q1 2025. The increase in adjusted EBITDA losses was primarily driven by higher stock-based compensation and increased operating expenses. #### Cash and Cash Equivalents As of March 31, 2026, cash and cash equivalents totaled $56.553 million, a substantial increase from $20.439 million as of December 31, 2025. #### Cash Flow from Operating Activities Net cash used in operating activities for the three months ended March 31, 2026, was - $6.480 million, compared to - $4.499 million used in the same period of 2025. #### Equity Funding TriSalus Life Sciences completed a public offering during the quarter, raising $42.625 million in net proceeds from the issuance of common stock. The company believes these proceeds provide sufficient cash runway to fully fund commercial expansion and pipeline development. #### Unique Operational Metrics A landmark, real-world PEDD® Study of over 16,800 patients found that PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance, despite PEDD patients having greater baseline clinical complexity. New clinical and preclinical PEDD data were also presented across multiple oncology and embolization applications. ### Outlook / Guidance TriSalus Life Sciences revised its 2026 revenue guidance to $54 million to $57 million, reflecting the impact of commercial expansion and the timing of FDA clearance for TriNav® Advance. The company believes the long-term growth opportunity for the PEDD platform remains substantial. ### Related Stocks - [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md) ## Related News & Research - [ESS Tech reschedules Q2 2026 results conference call to Tuesday evening](https://longbridge.com/en/news/295407778.md) - [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md) - [Illinois Tool Works declares Q3 2026 dividend of R$ 1.48 per unit](https://longbridge.com/en/news/295435249.md) - [CitroTech Provides Q2 2026 Business Update in Letter to Shareholders](https://longbridge.com/en/news/295561956.md) - [Bath & Body Works announces R$ 0.17 per unit distribution for Q3 2026](https://longbridge.com/en/news/295434486.md)